SEC filing record
Primary Source · SEC.gov

Chemomab Therapeutics Ltd.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-08-09Last filing 2024-08-09

Raised

$10M

Investors

10

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Chemomab Therapeutics Ltd. is a Israel corporation that filed a Form D with the SEC on August 9, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Chemomab Therapeutics Ltd. reported $10,000,000 sold from 10 investors of a $10,000,000 total offering as of the Form D filed August 9, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Oppenheimer & Co. Inc. (CRD 249), associated with None as the recipient of sales compensation soliciting in CA, NY. Sales commissions are reported as $400,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is Kiryat Atidim, Building 7, Tel Aviv.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001534248
Entity NameChemomab Therapeutics Ltd.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationIsrael
Issuer AddressKiryat Atidim, Building 7, Tel Aviv
Phone972-77-331-0156
Former NamesAnchiano Therapeutics Ltd. (until March 17, 2021); BioCancell Ltd. (until November 3, 2015)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateJuly 29, 2024
Filing DateAugust 9, 2024
Accession Number0001231919-24-000064
Total Offering Amount$10,000,000
Total Amount Sold$10,000,000
Amount Remaining$0
Total Investors10
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$400,000 (to Oppenheimer & Co. Inc.)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)L3
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Aug 9, 2024

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

closed

Latest event New filer · Aug 9, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2024-08-09, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-08-09: 3 related persons added and 4 removed against the filing of 2021-03-30; 8 now listed. The names are in the Terminal feed.

Adi Mor

Executive Officer, Director · Tel Aviv, L3

Sigal Fattal

Executive Officer · Ramat Gan, L3

Matthew Frankel

Executive Officer · Tel Aviv, L3

Nissim Darvish

Director · Tel Aviv, L3

Alan Charles Moses

Director · Tel Aviv, L3

Claude Charles Nicaise

Director · Cheshire, CT

Neil Harris Cohen

Director · Cambridge, MA

Jill Harris Quigley

Director · Tel Aviv, L3

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Oppenheimer & Co. Inc.CRD 249 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA, NY

Questions About Chemomab Therapeutics Ltd.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Chemomab Therapeutics Ltd.?

Chemomab Therapeutics Ltd. is a Israel corporation that filed a Form D with the SEC on August 9, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Chemomab Therapeutics Ltd. legit?

AltStreet does not rate legitimacy; it reports the public record. Chemomab Therapeutics Ltd. filed a Form D with the SEC on August 9, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $10,000,000 sold to 10 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Chemomab Therapeutics Ltd. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Chemomab Therapeutics Ltd. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Chemomab Therapeutics Ltd. raised?

Chemomab Therapeutics Ltd. reported $10,000,000 sold from 10 investors of a $10,000,000 total offering as of the Form D filed August 9, 2024.

Who can invest in Chemomab Therapeutics Ltd.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Chemomab Therapeutics Ltd.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Chemomab Therapeutics Ltd. and how are they paid?

The Form D names Oppenheimer & Co. Inc. (CRD 249), associated with None as the recipient of sales compensation soliciting in CA, NY. Sales commissions are reported as $400,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Chemomab Therapeutics Ltd.?

The Form D lists 8 related persons: Adi Mor, executive officer, director; Sigal Fattal, executive officer; Matthew Frankel, executive officer; Nissim Darvish, director; Alan Charles Moses, director; Claude Charles Nicaise, director; Neil Harris Cohen, director; Jill Harris Quigley, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Chemomab Therapeutics Ltd. located?

The issuer's address on its SEC filings is Kiryat Atidim, Building 7, Tel Aviv. Its phone number of record is 972-77-331-0156. It is organized under the laws of Israel.

How long is the Chemomab Therapeutics Ltd. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Chemomab Therapeutics Ltd.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.